Kyoto Trial to Evaluate the Safety and Efficacy of Tacrolimus in the iPSC-based Therapy for Parkinson's Disease

General Information

Description To evaluate the safety and efficacy of tacrolimus in patients with Parkinson's disease after transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors into the corpus striatum.
Clinical trials phase Phase 3
Start date (estimated) 2018-08-01
End date (estimated) 2023-12-31
Clinical feature
Label Parkinson's disease
Link http://purl.obolibrary.org/obo/DOID_14330
Description A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000033565
Other study identifiers
Name UMIN000033565
Description UMIN Clinical Trials Registry (UMIN-CTR)
Source weblink https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038279
Public contact
Email neuroofc@kuhp.kyoto-u.ac.jp
First name Nobukatsu
Last name Sawamoto
Phone 075-751-3771
City Kyoto
Country
Japan
Address freetext 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507
Sponsors Kyoto University Hospital

Cells

Which differentiated cell type is used
Label dopaminergic neuron
Link http://purl.obolibrary.org/obo/CL_0000700
Description A neuron that releases dopamine as a neurotransmitter.

Recruitment

Recruitment Status Suspended
Estimated number of participants 7